Computer model of IL-6-dependent rheumatoid arthritis in F759 mice

Area of Science:

• Immunology
• Molecular Biology
• Computational Biology

Background:

• The interleukin-6 (IL-6) amplifier, characterized by simultaneous signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappa B (NF-κB) activation in synovial fibroblasts, contributes to joint immune cell infiltration.
• This process in F759 mice models human rheumatoid arthritis, but the precise kinetics and regulatory mechanisms of STAT3 and NF-κB's role remain unclear.

Purpose of the Study:

• To elucidate the molecular mechanisms and kinetics of the STAT3-NF-κB complex formation and function in F759 arthritis.
• To establish a computational model for simulating the IL-6 amplifier pathway and its role in inflammatory responses.
• To identify potential therapeutic targets for IL-6 amplifier-dependent chronic inflammatory diseases.

Main Methods:

• Utilized in vitro and in silico approaches to study the STAT3-NF-κB complex.
• Developed a computer model simulating IL-6 and IL-17 signaling pathways.
• Investigated the effects of anti-IL-6, anti-IL-17, and anti-TNFα antibody treatments at different disease phases.

Main Results:

• The STAT3-NF-κB complex was observed in both cytoplasm and nucleus, accumulating at IL-6 promoter binding sites.
• The computational model demonstrated that IL-6 and IL-17 signaling promote STAT3-NF-κB complex formation, accelerating inflammatory gene expression (IL-6, epiregulin, CCL2) and promoting synovium cell growth.
• Anti-IL-6 antibody treatment effectively inhibited inflammation late-phase, while anti-IL-17 showed efficacy only in the early phase, indicating differential pathway dependence.

Conclusions:

• The study reveals the molecular mechanism of F759 arthritis, driven by the IL-6 amplifier pathway.
• The findings highlight the critical role of IL-6 and IL-17 in the early phase and IL-6 in the late phase of the disease.
• In silico recapitulation and therapeutic targeting of the IL-6 amplifier present a promising strategy for chronic inflammatory diseases.